\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ palpable\\ thyroid\\ nodules\\.\\ \\ currently\\ taking\\ thyroid\\ replacement\\ therapy\\ under\\ endocrinology\\ care\\ and\\ is\\ euthyroid\\.\ \(0\)\
\-\ closely\\ monitor\\ thyroid\\ function\\.\\ \\ \\ patients\\ are\\ at\\ risk\\ for\\ developing\\ thyroid\\ lymphoma\\.\\ \\ monitor\\ for\\ other\\ autoimmune\\ disorders\\.\\ screen\\ family\\ members\\.\ \(0\)\
\-\ enlarged\\,\\ hypoechoic\\,\\ and\\ heterogenous\\ grainy\\ with\\ multiple\\ tiny\\ 1\\ \\-\\ 6\\ mm\\ nodules\\.\\ \\ late\\ stage\\ may\\ appear\\ fibrotic\\.\\ \\ the\\ thryoid\\ gland\\ most\\ often\\ has\\ normal\\ sonographic\\ blood\\ flow\\.\ \(0\)\
\-\ hashimoto\\'s\\ thyroiditis\ \(0\)\
\-\ graves\\ disease\\ if\\ subclinical\\.\\ \\ thyroid\\ blood\\ flow\\ may\\ be\\ helpful\\ in\\ differentiating\\ disease\\ spectrum\\.\\ \\ \ \(0\)\
\-\ riedels\\ thryoiditis\\ if\\ fibrosis\\ is\\ predominant\\ pattern\\ but\\ hashimotos\\ is\\ confined\\ to\\ gland\\.\ \(0\)\
\-\ primary\\ thyroid\\ lymphoma\\.\\ closely\\ associated\\ with\\ hashimoto\\'s\\ thyroiditis\ \(0\)\
\-\ dequervain\\ thyroiditis\\ is\\ subacute\\ viral\\ induced\\ thryoiditis\\ with\\ sonographically\\ edematous\\ and\\ hypoechoic\\ thyroid\\ gland\\.\ \(0\)\
\-\ mom\\ with\\ history\\ of\\ autoimmune\\ thyroiditis\\.\\ \\ patient\\ complains\\ of\\ fatigue\\.\ \(0\)\
\-\ the\\ young\\ male\\'s\\ mother\\ has\\ history\\ of\\ thyroiditis\\.\\ \\ his\\ enlarged\\ gland\\ and\\ clinical\\ hypothyroidism\\ increased\\ the\\ probabilty\\ of\\ his\\ autoimmune\\ thyroiditis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroiditis\\:\\ 0\\.465277680465472\ \(0\)\
\-\ thyroid\\:\\ 0\\.38509103885532653\ \(0\)\
\-\ autoimmune\\:\\ 0\\.23494051720155879\ \(0\)\
\-\ gland\\:\\ 0\\.2274608980595692\ \(0\)\
\-\ thryoiditis\\:\\ 0\\.2238960703032642\ \(0\)\
\-\ hashimoto\\:\\ 0\\.1744438481182233\ \(0\)\
\-\ closely\\:\\ 0\\.15037113312846176\ \(0\)\
\-\ monitor\\:\\ 0\\.14300559799684476\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.1196242872348309\ \(0\)\
\-\ grainy\\:\\ 0\\.1119480351516321\ \(0\)\
\-\ hashimotos\\:\\ 0\\.1119480351516321\ \(0\)\
\-\ probabilty\\:\\ 0\\.1119480351516321\ \(0\)\
\-\ nodules\\:\\ 0\\.11124127056937241\ \(0\)\
\-\ euthyroid\\:\\ 0\\.10344200085853743\ \(0\)\
\-\ thryoid\\:\\ 0\\.10344200085853743\ \(0\)\
\-\ subclinical\\:\\ 0\\.09657461220481668\ \(0\)\
\-\ enlarged\\:\\ 0\\.09544224811337576\ \(0\)\
\-\ flow\\:\\ 0\\.0932522281442014\ \(0\)\
\-\ endocrinology\\:\\ 0\\.08642993227234809\ \(0\)\
\-\ fibrotic\\:\\ 0\\.08642993227234809\ \(0\)\
\-\ members\\:\\ 0\\.08568597034530122\ \(0\)\
\-\ sonographically\\:\\ 0\\.08568597034530122\ \(0\)\
\-\ his\\:\\ 0\\.08490874583470452\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08338075139704122\ \(0\)\
\-\ differentiating\\:\\ 0\\.08309286682041343\ \(0\)\
\-\ mom\\:\\ 0\\.08252199116888725\ \(0\)\
\-\ if\\:\\ 0\\.08134551081301664\ \(0\)\
\-\ blood\\:\\ 0\\.0813086867596202\ \(0\)\
\-\ predominant\\:\\ 0\\.07871588976601698\ \(0\)\
\-\ tiny\\:\\ 0\\.07754628007757867\ \(0\)\
\-\ is\\:\\ 0\\.07668181759085116\ \(0\)\
\-\ edematous\\:\\ 0\\.07518556656423088\ \(0\)\
\-\ confined\\:\\ 0\\.07488254836640726\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.07294818688794484\ \(0\)\
\-\ screen\\:\\ 0\\.07220422496089797\ \(0\)\
\-\ spectrum\\:\\ 0\\.07105650932553266\ \(0\)\
\-\ may\\:\\ 0\\.07045417421308243\ \(0\)\
\-\ induced\\:\\ 0\\.06941786368615874\ \(0\)\
\-\ taking\\:\\ 0\\.06780320947865374\ \(0\)\
\-\ fatigue\\:\\ 0\\.06780320947865374\ \(0\)\
\-\ developing\\:\\ 0\\.06699022262519115\ \(0\)\
\-\ helpful\\:\\ 0\\.06637651407331258\ \(0\)\
\-\ late\\:\\ 0\\.06608079823422408\ \(0\)\
\-\ heterogenous\\:\\ 0\\.06593557034408933\ \(0\)\
\-\ subacute\\:\\ 0\\.0655099225826979\ \(0\)\
\-\ viral\\:\\ 0\\.06457065233958337\ \(0\)\
\-\ has\\:\\ 0\\.0639495179985183\ \(0\)\
\-\ sonographic\\:\\ 0\\.06299676470532771\ \(0\)\
\-\ replacement\\:\\ 0\\.06288366147618843\ \(0\)\
\-\ disorders\\:\\ 0\\.061806513105391106\ \(0\)\
\-\ complains\\:\\ 0\\.06091182939306408\ \(0\)\
\-\ mother\\:\\ 0\\.05981214361741545\ \(0\)\
\-\ disease\\:\\ 0\\.05876849431243351\ \(0\)\
\-\ fibrosis\\:\\ 0\\.05864253392897714\ \(0\)\
\-\ under\\:\\ 0\\.057945535754206925\ \(0\)\
\-\ and\\:\\ 0\\.057860017132493176\ \(0\)\
\-\ young\\:\\ 0\\.05772173112876441\ \(0\)\
\-\ function\\:\\ 0\\.056660123136272\ \(0\)\
\-\ stage\\:\\ 0\\.055745856917073934\ \(0\)\
\-\ appear\\:\\ 0\\.05513214836519537\ \(0\)\
\-\ family\\:\\ 0\\.05507243236661604\ \(0\)\
\-\ with\\:\\ 0\\.054828869968926754\ \(0\)\
\-\ of\\:\\ 0\\.05479612929473034\ \(0\)\
\-\ currently\\:\\ 0\\.05377353319261651\ \(0\)\
\-\ history\\:\\ 0\\.05348944069843071\ \(0\)\
\-\ pattern\\:\\ 0\\.05226282322849937\ \(0\)\
\-\ mm\\:\\ 0\\.050096721275307475\ \(0\)\
\-\ care\\:\\ 0\\.0500175493007399\ \(0\)\
\-\ risk\\:\\ 0\\.0500175493007399\ \(0\)\
\-\ palpable\\:\\ 0\\.04917878969960299\ \(0\)\
\-\ often\\:\\ 0\\.04567613643849657\ \(0\)\
\-\ clinical\\:\\ 0\\.0443638174055439\ \(0\)\
\-\ for\\:\\ 0\\.04243398541133968\ \(0\)\
\-\ the\\:\\ 0\\.04190365590112377\ \(0\)\
\-\ therapy\\:\\ 0\\.04022054456897186\ \(0\)\
\-\ patients\\:\\ 0\\.039379811881008246\ \(0\)\
\-\ increased\\:\\ 0\\.03785361690607572\ \(0\)\
\-\ associated\\:\\ 0\\.03689617082723074\ \(0\)\
\-\ most\\:\\ 0\\.03643102963212271\ \(0\)\
\-\ other\\:\\ 0\\.036353031826160086\ \(0\)\
\-\ but\\:\\ 0\\.0346159739821091\ \(0\)\
\-\ multiple\\:\\ 0\\.03423937867228464\ \(0\)\
\-\ male\\:\\ 0\\.03116747124466375\ \(0\)\
\-\ normal\\:\\ 0\\.02858124449972185\ \(0\)\
\-\ be\\:\\ 0\\.028396910817218544\ \(0\)\
\-\ are\\:\\ 0\\.026562479865524357\ \(0\)\
\-\ at\\:\\ 0\\.02644054657782411\ \(0\)\
\-\ patient\\:\\ 0\\.022768054594355398\ \(0\)\
\-\ no\\:\\ 0\\.02276377205601416\ \(0\)\
\-\ to\\:\\ 0\\.017500299600997186\ \(0\)\
\-\ in\\:\\ 0\\.017414163162605443\ \(0\)\
